CERO THERAPEUTICS HOLDINGS, INC. (CERO): debt financing — CERo Therapeutics issues $750K convertible note to Keystone Capital with conversion price floor at $0.05

CERO THERAPEUTICS HOLDINGS, INC.

Issued convertible promissory note to Keystone Capital Partners; purchase price $750,000, principal face value $937,500.
Note bears 10% interest, matures August 6, 2027; conversion price is lesser of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.
Beneficial ownership limitation of 4.99%; company must file registration statement for resale of conversion shares.
Offered under Section 4(a)(2) and Rule 506(b) exemption; no public offering.
Maximum aggregate borrowing up to $1,000,000 under the note.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $750,000 purchase price, $937,500 principal face value, up to $1,000,000 aggregate with Keystone Capital Partners, LLC at 10% per annum maturing August 6, 2027.

Instrument: convertible notes
Principal: $750,000 purchase price, $937,500 principal face value, up to $1,000,000 aggregate
Counterparty: Keystone Capital Partners, LLC
Rate: 10% per annum
Maturity: August 6, 2027
Event: incurrence

Exact text from the filing

On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for purchase price of $750,000.

Security: convertible note
Purchaser: Keystone Capital Partners, LLC
Consideration: purchase price of $750,000

Exact text from the filing

On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

CERO THERAPEUTICS HOLDINGS, INC. entered into Convertible Promissory Note with Keystone Capital Partners, LLC valued at Purchase price $750,000; principal face value $937,500; maximum aggregate borrowings $1,000,000; int (effective 2026-03-06).

Action: entry
Agreement: notes offering
Counterparty: Keystone Capital Partners, LLC
Value: Purchase price $750,000; principal face value $937,500; maximum aggregate borrowings $1,000,000; int
Effective: 2026-03-06

Exact text from the filing

On March 6, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for a purchase price of $750,000, having a principal face value of $937,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-025817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.